Moxifloxacin Hydrochloride, Ophthalmic — Competitive Intelligence Brief

Moxifloxacin Hydrochloride, Ophthalmic (Moxifloxacin Hydrochloride, Ophthalmic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic. Area: Ophthalmology / Infectious Disease.

phase 3 Fluoroquinolone antibiotic DNA gyrase; Topoisomerase IV Ophthalmology / Infectious Disease Small molecule

Target snapshot

Moxifloxacin Hydrochloride, Ophthalmic (Moxifloxacin Hydrochloride, Ophthalmic) — Laboratorios Sophia S.A de C.V.. Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Moxifloxacin Hydrochloride, Ophthalmic TARGET	Moxifloxacin Hydrochloride, Ophthalmic	Laboratorios Sophia S.A de C.V.	phase 3	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin Injectable Product	Moxifloxacin Injectable Product	Fundacion Clinic per a la Recerca Biomédica	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin (M)	Moxifloxacin (M)	Global Alliance for TB Drug Development	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
gatifloxacin ophthalmic solution 0.3%	gatifloxacin ophthalmic solution 0.3%	Allergan	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Placebo Drink + Moxifloxacin Capsule	Placebo Drink + Moxifloxacin Capsule	University of the Pacific	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin ophthalmic solution 0.5%	Moxifloxacin ophthalmic solution 0.5%	Ophthalmic Consultants of Boston	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV
Moxifloxacin (Avelox)	Moxifloxacin (Avelox)	Connect Biopharma Australia Pty Ltd	marketed	Fluoroquinolone antibiotic	DNA gyrase; Topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic class)

1. Bayer · 4 drugs in this class
2. Allergan · 4 drugs in this class
3. Mackay Memorial Hospital · 2 drugs in this class
4. Indiana University School of Medicine · 2 drugs in this class
5. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
6. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
7. Connect Biopharma Australia Pty Ltd · 1 drug in this class
8. GlaxoSmithKline · 1 drug in this class
9. Global Alliance for TB Drug Development · 1 drug in this class
10. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class